Resource Library

Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.

At Castor, we hope to see DCT extend into all trials as we work alongside researchers in the pursuit of the ultimate goal of democratized clinical research.

announced two executive appointments to accelerate the company’s growth and impact on the industry. Kimberly Tableman as Chief Clinical Development Officer (CCDO) and Anna Wozniak as Chief Financial & Development Officer (CFDO).

Since it was first instituted in the 1960s, written consent to participate in research studies has undergone very little change other than tightening regulations and increased participant education of their rights.

Decentralized clinical trials (DCT) are collecting many kinds of data remotely, and this data is only expected to grow in volume. From wireless patches monitoring vitals to an ever-growing list of mobile-connected products, there are new data sources popping up almost everywhere.

eConsent accelerates enrollment, increases retention, and reduces site burden. Find out why it’s the way of the future for clinical trials here.

Download this case study to learn how Castor responded to the disruptive impact of COVID-19 and helped the COVID-RED study implement decentralized clinical trial methods to recruit over 17,825 participants in just 15 weeks.

Castor is supporting the next generation of digital therapeutics that can improve patient lives with disease-modifying potential.

Castor and Lightship discuss the infrastructure needs for providing the best patient experience and ensuring data integrity in decentralized clinical trials.

eConsent accelerates enrollment, increases retention, and reduces site burden. Learn why it’s the way of the future for clinical trials.